Results 111 to 120 of about 157,441 (307)

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

The bargaining model of depression [PDF]

open access: yes, 2002
Minor depression—low mood often accompanied by a loss of motivation—is almost certainly an adaptation to circumstances that, in ancestral environments, imposed a fitness cost. It is, in other words, the psychic equivalent of physical pain.
Hagen, Edward H
core  

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Carbamazepine is licensed in the United Kingdom for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia. The related compounds oxcarbazepine and eslicarbazepine are licensed for the treatment of epilepsy. These drugs can cause immune‐mediated hypersensitivity reactions, which typically affect the skin, and can be of variable severity ...
Lucy Galloway   +24 more
wiley   +1 more source

Biomaterial design strategies for enhancing mitochondrial transplantation therapy

open access: yesBMEMat, EarlyView.
Biomaterials to facilitate mitochondrial transplantation therapy: biomaterials as barriers to protect mitochondria from pathophysiological microenvironments, like osmotic stress caused by the excessive concentration of calcium ion, reactive oxygen species, and advanced glycation end products; biomaterials integrating with biochemical cues to improve ...
Shaoyang Kang   +12 more
wiley   +1 more source

Homocysteine levels in first-episode patients with psychiatric disorders

open access: yesFrontiers in Psychiatry
A high homocysteine (Hcy) level is a risk factor for schizophrenia, depression, and bipolar disorder. However, the role of hyperhomocysteinemia as either an independent factor or an auxiliary contributor to specific psychiatric symptoms or disorders ...
Ning Fan   +9 more
doaj   +1 more source

Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome.

open access: yes, 2013
BACKGROUND: The functional outcome of Bipolar Disorder (BD) is highly variable. This variability has been attributed to multiple demographic, clinical and cognitive factors.
Ayuso-Mateos, José L   +9 more
core   +1 more source

Mitral Transcatheter Edge‐to‐Edge Repair in Patients With Advanced Heart Failure: A Single‐Center Experience and Insights Into Anatomical and Clinical Determinants of Procedural Complexity

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Advanced heart failure (HF) remains a clinical challenge, and mitral transcatheter edge‐to‐edge repair (M‐TEER) has emerged as a potential bridging strategy. Aims To describe the clinical outcomes of M‐TEER in a single‐center cohort of patients with advanced HF and to identify anatomical and clinical features potentially associated ...
Pedro Castilhos de Freitas Crivelaro   +8 more
wiley   +1 more source

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy   +3 more
wiley   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy